"Ifosfamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
Descriptor ID |
D007069
|
MeSH Number(s) |
D02.455.526.728.650.730.243.250 D02.705.672.500.243.250 D03.383.533.500
|
Concept/Terms |
Ifosfamide- Ifosfamide
- Isofosfamide
- Isophosphamide
- Iphosphamide
- Iso-Endoxan
- Iso Endoxan
NSC-109,724- NSC-109,724
- NSC 109,724
- NSC109,724
- NSC-109724
- NSC 109724
- NSC109724
|
Below are MeSH descriptors whose meaning is more general than "Ifosfamide".
Below are MeSH descriptors whose meaning is more specific than "Ifosfamide".
This graph shows the total number of publications written about "Ifosfamide" by people in this website by year, and whether "Ifosfamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 3 | 3 | 6 |
1995 | 2 | 4 | 6 |
1996 | 3 | 3 | 6 |
1997 | 1 | 4 | 5 |
1998 | 2 | 8 | 10 |
1999 | 2 | 6 | 8 |
2000 | 1 | 7 | 8 |
2001 | 2 | 3 | 5 |
2002 | 1 | 4 | 5 |
2003 | 0 | 3 | 3 |
2004 | 1 | 3 | 4 |
2005 | 0 | 3 | 3 |
2006 | 1 | 4 | 5 |
2007 | 0 | 4 | 4 |
2008 | 1 | 7 | 8 |
2009 | 2 | 7 | 9 |
2010 | 1 | 2 | 3 |
2011 | 0 | 5 | 5 |
2012 | 1 | 2 | 3 |
2013 | 2 | 1 | 3 |
2014 | 0 | 5 | 5 |
2015 | 0 | 5 | 5 |
2017 | 1 | 2 | 3 |
2018 | 0 | 2 | 2 |
2019 | 0 | 3 | 3 |
2020 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
2022 | 0 | 3 | 3 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ifosfamide" by people in Profiles.
-
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology. J Clin Oncol. 2023 11 01; 41(31):4842-4848.
-
Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy. Cancer. 2022 12 01; 128(23):4150-4156.
-
Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma. Pediatr Hematol Oncol. 2023 May; 40(4):422-428.
-
Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. Cancer Med. 2022 09; 11(18):3471-3478.
-
Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma. Cancer Rep (Hoboken). 2022 07; 5(7):e1581.
-
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Lancet Oncol. 2021 09; 22(9):1312-1321.
-
Splenic embolization to continue chemotherapy in a child with hypersplenism-related thrombocytopenia. Pediatr Blood Cancer. 2021 02; 68(2):e28613.
-
A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. Lancet Oncol. 2020 01; 21(1):145-161.
-
Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. Br J Haematol. 2019 10; 187(1):39-48.
-
Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials. Eur J Cancer. 2019 05; 112:98-106.